Skip to main content
. 2011 Aug 13;12(6):609–615. doi: 10.1007/s10194-011-0366-9

Table 2.

Main study endpoints in the two study treatment groups

Frovatriptan Rizatriptan p
Pain relief episodes at 2 h 25 (58) 27 (64) NS
Pain free episodes at 2 h 15 (31) 20 (34) NS
Pain relief episodes at 24 h 35 (81) 31 (74) NS
Pain free episodes at 24 h 33 (67) 36 (61) NS
Recurrent episodes at 24 h 5 (10) 19 (32) <0.01

Data are reported as absolute (n) and relative (%) frequency. P refers to the statistical significance of the difference between the two study drugs